鞍山市利福平耐药肺结核患者危险因素分析  

Analysis of risk factors in patients with rifampicin-resistant pulmonary tuberculosis in Anshan City

作　　者：李笑男[1] 曹宏伟[2] LI Xiao-nan;CAO Hong-wei(Tuberculosis Prevention and Control Department,Anshan Center for Disease Control and Prevention nshan Liaoning,114003,China;Tuberculosis Prevention and Control Institute,Liaoning Center for Disease Control and Prevention,Shenyang Liaoning,110005,China)

机构地区：[1]鞍山市疾病预防控制中心结核病防制科,辽宁鞍山114003 [2]辽宁省疾病预防控制中心结核病防治所,辽宁沈阳110005

出　　处：《职业与健康》2022年第1期128-131,共4页Occupation and Health

摘　　要：目的了解鞍山市的利福平耐药肺结核患者发生耐药的相关危险因素,为制定本地利福平耐药肺结核防控策略提供参考依据。方法收集2017年1月—2019年12月全国结核病疫情报告系统鞍山市的330例利福平耐药结核病(rifampicin resistant tuberculosis,RR-TB)患者和5409例非利福平耐药(non-rifampicin resistant tuberculosis,Non-RR-TB)患者的临床资料(性别、年龄、家庭收入、吸烟史、居住地、复治、治疗中断和第1次就诊机构),进行回顾性分析。结果不同性别、年龄、家庭收入及吸烟史的利福平耐药肺结核的发生比较,差异均无统计学意义(均P>0.05);在是否为复治患者、居住地、治疗过程的连续性及第1次就诊机构变量下,利福平耐药肺结核的发生比较,差异均有统计学意义(均P<0.05)。复治(OR=5.135,95%CI=3.964~6.52)和治疗过程是否中断(OR=1.992,95%CI=1.333~2.990)为利福平耐药肺结核的危险因素。结论复治和曾经中断治疗的患者易出现利福平耐药性,为利福平耐药肺结核患者的危险因素,应有针对的采取相应的控制措施,避免患者耐药性的产生。Objective To explore the risk factors of drug resistance in patients with rifampicin-resistant pulmonary tuberculosis in Anshan City,provide the basis for formulating local prevention and control strategies against ifampicin-resistant pulmonary tuberculosis.Methods The clinical data(gender,age,family income,smoking history,place of residence,retreatment,interruption of treatment,and institution of the first visit)of 330 patients with rifampicin resistant tuberculosis(RR-TB)and 5409 patients with non-rifampicin resistant tuberculosis(Non-RR-TB)in Anshan City,who were reported in the national tuberculosis reporting system from January 2017 to December 2019 were collected for the retrospective analysis.Results There were no statistically significant differences in the occurrence of RR-TB among the groups in different gender,age,family income and smoking history(all P>0.05).The differences in the occurrence of RR-TB were statistically significant among the groups in different variables of retreatment patients,place of residence,family income,and smoking history(all P<0.05).Retreatment(OR=5.135,95%CI=3.964-6.52)and whether the treatment process was interrupted(OR=1.992,95%CI=1.333-2.990)were the risk factor of RR-TB.Conclusion Patients who have been retreated and who have interrupted treatment are prone to rifampicin resistance,which are the risk factors for RRTB patients,so the corresponding control measures should be taken to avoid the development of drug resistance in patients.

关 键 词：结核分枝杆菌 利福平耐药肺结核 危险因素 

分 类 号：R978.1[医药卫生—药品]